We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Roche Acquires Signature Diagnostics to Advance Translational Research

By LabMedica International staff writers
Posted on 16 Feb 2015
Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays.

Signature Diagnostics is a privately held translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers (including colorectal and lung), constructed from multicenter prospective clinical studies. Signature uses the samples from its biobanks along with accompanying clinical progression and genetic data to develop and validate circulating cell free DNA (cfDNA) tests, toward advancing cost-effective noninvasive monitoring of patient treatment response. Signature will be integrated into Roche Sequencing Unit and will continue to focus on expanding its innovative genomic signature portfolio.

"Biobanks play an important role in uncovering the cause or origin of disease such as cancer which is important in translational research and the development of personalized therapies for patients," said Roland Diggelmann, COO, Roche Diagnostics, "Signature represents a unique bridge between high value cancer biobanks and NGS assay development. Roche plans to leverage Signature's expertise in both of these areas to accelerate the development of targeted NGS-based diagnostics in the future. Biobanks can also be used for biomarker discovery and hypothesis testing with Pharma."

"We are very pleased Roche recognizes the importance of high-quality longitudinal cancer biobanks for the development of novel NGS-based diagnostics," says Andre Rosenthal, PhD, CEO of Signature, "Joining forces with Roche is very exciting as it will allow us to further develop our NGS assays for sequencing tests using cfDNA, which may advance the development of noninvasive treatment-response monitoring for cancer patients."

Signature products are currently for research use only.

Related Links:

Roche
Signature Diagnostics



Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Apolipoprotein A-I Assay
Apo A-I Assay
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries